Pamela Schaefer
During the last decade we have seen marked progress in brain tumor imaging. With the development of advanced MRI techniques, we have moved from anatomic to physiologic imaging of brain tumors. For example, perfusion MRI has allowed determination of tumor grade and differentiation of recurrent tumor from necrosis with elevated cerebral blood volume … more »
Evangelia I. Zacharaki
High-grade brain gliomas have a terrible prognosis, with mean survival just over one year even though combinations of surgical removal, radiotherapy, and chemotherapy are used in clinical practice. Our overarching hypothesis is that advanced modeling and analysis methods, which combine diverse information from patient multiparametric images, tumor histologic and molecular profile, biophysical models … more »
Apostolos J. Tsiouris
Bevacizumab is a monoclonal antibody that is now routinely administered intravenously for the treatment of recurrent glioblastomas, and is thought to inhibit vascular endothelial growth factor (VEGF) and therefore angiogenesis. There has been extensive debate in the literature as to the histopathologic effects of bevacizumab on glioblastomas. How to best determine … more »
Benjamin M. Ellingson
Investigators from our team recently discovered that patients with glioma having mutation of the isocitrate dehydrogenase-1 (IDH1) gene tended to have larger, nonenhancing tumors localized in the frontal lobe (Lai et al, J Clin Oncol, 2011; 29:4482-90). Using an approach similar to lesion-symptom mapping, we developed a technique where MR images of the … more »
Ajay Gupta
Robert J. Young
In this article, we investigated the utility of diffusion-weighted imaging in monitoring patients being treated for glioblastoma. We found that some treated glioblastomas developed diffusion-restricted nonenhancing lesions that subsequently transformed into enhancing lesions. We concluded that these quantitative … more »
Kensuke Tateishi
Nobutaka Kawahara
Tissue hypoxia is a typical feature of highly malignant tumors, and glioblastoma, the most malignant tumor in the central nervous system, is not an exception. Indeed, glioblastomas are characterized by necrotic regions that distinguish them from less malignant gliomas. In addition, … more »
Leland S. Hu
MRI biomarkers have the potential to greatly impact glioma care. However, the medical community has been slow to adopt these, in part, because we don’t yet fully understand their basic relationships with histologic correlates.
For instance, we have long assumed that pMRI measurements (ie, relative cerebral blood volume, rCBV) correspond highly with … more »
Rajan Jain
Recent improvements in determining molecular/genomic expression of any tissue have brought us one step closer to personalized treatment for many disease processes, notably in oncology. This could be especially true for glioblastomas as the currently available treatment options have not improved the dismal survival. One of the major reasons for this is that current … more »